Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving in...
Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin
About this item
Full title
Author / Creator
Publisher
London: Nature Publishing Group UK
Journal title
Language
English
Formats
Publication information
Publisher
London: Nature Publishing Group UK
Subjects
More information
Scope and Contents
Contents
Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM). This study further investigated the relationship between pioglitazone use and the risk of developing Alzheimer's disease (AD) in patients newly diagnosed with T2DM, and examined the potential...
Alternative Titles
Full title
Pioglitazone use increases risk of Alzheimer's disease in patients with type 2 diabetes receiving insulin
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_1a736a74e5e3400db0f509f97fecee3e
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_1a736a74e5e3400db0f509f97fecee3e
Other Identifiers
ISSN
2045-2322
E-ISSN
2045-2322
DOI
10.1038/s41598-023-33674-2
